

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 September 2003 (12.09.2003)

PCT

(10) International Publication Number
WO 03/074041 A1

(51) International Patent Classification⁷: **A61K 31/196,**
9/20

Jurij [US/US]; 5 Brantwood Terrace, Hackettstown, NJ
07840 (US). JOSH, Yatindra [US/US]; 38 Walker Drive,
Princeton, NJ 08540 (US).

(21) International Application Number: PCT/EP03/02322

(22) International Filing Date: 6 March 2003 (06.03.2003)

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellect-
tual Property, CH-4002 Basel (CH).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/362,351 7 March 2002 (07.03.2002) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR,
TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except AT, US*): NO-
VARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for AT only*): NOVARTIS PHARMA GMBH
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): KARNACHI, Anees
Abdulquadar [IN/US]; 34 Nostrand Road, Hillsborough,
NJ 08844 (US). KHALED, Maha, Y. [US/US]; 27 Pebble
Beach Drive, Livingston, NJ 07039 (US). HOLINEJ,

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: PHARMACEUTICAL COMPOSITIONS

(57) Abstract: A method of treating a cyclooxygenase-2 dependent disorder or condition comprising administering 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid in an amount effective to treat such a disorder or condition for about 24 hours, comprising administering orally once a day to a human in need of such treatment one or more immediate release pharmaceutical compositions comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid, and compositions suitable for use in such methods.

WO 03/074041 A1